IN2014DN09417A - - Google Patents
Info
- Publication number
- IN2014DN09417A IN2014DN09417A IN9417DEN2014A IN2014DN09417A IN 2014DN09417 A IN2014DN09417 A IN 2014DN09417A IN 9417DEN2014 A IN9417DEN2014 A IN 9417DEN2014A IN 2014DN09417 A IN2014DN09417 A IN 2014DN09417A
- Authority
- IN
- India
- Prior art keywords
- present
- specific antibodies
- antibodies
- specificity
- affinity
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261645302P | 2012-05-10 | 2012-05-10 | |
| PCT/US2013/040575 WO2013170168A1 (en) | 2012-05-10 | 2013-05-10 | Multi-specific monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09417A true IN2014DN09417A (US07915450-20110329-C00039.png) | 2015-07-17 |
Family
ID=49551307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9417DEN2014 IN2014DN09417A (US07915450-20110329-C00039.png) | 2012-05-10 | 2013-05-10 |
Country Status (13)
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3553089A1 (en) | 2012-05-10 | 2019-10-16 | Bioatla, LLC | Multi-specific monoclonal antibodies |
| KR102351838B1 (ko) | 2013-08-05 | 2022-01-18 | 트위스트 바이오사이언스 코포레이션 | 드 노보 합성된 유전자 라이브러리 |
| DK3143138T3 (da) | 2014-05-13 | 2022-04-25 | Bioatla Inc | Betinget aktive biologiske proteiner |
| ES2913865T3 (es) | 2014-08-28 | 2022-06-06 | Bioatla Inc | Receptores de antígeno quimérico condicionalmente activos para células T modificadas |
| US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| US10669304B2 (en) | 2015-02-04 | 2020-06-02 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| EP3350314A4 (en) | 2015-09-18 | 2019-02-06 | Twist Bioscience Corporation | BANKS OF OLIGONUCLEIC ACID VARIANTS AND SYNTHESIS THEREOF |
| CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
| WO2017123537A1 (en) | 2016-01-12 | 2017-07-20 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
| US10697972B2 (en) | 2016-01-12 | 2020-06-30 | Bioatla, Llc | Diagnostics using conditionally active antibodies |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| PT3455261T (pt) | 2016-05-13 | 2022-11-11 | Bioatla Llc | Anticorpos anti-ror2, fragmentos de anticorpo, seus imunoconjugados e suas utilizações |
| CN110248724B (zh) | 2016-09-21 | 2022-11-18 | 特韦斯特生物科学公司 | 基于核酸的数据存储 |
| WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| CA3054303A1 (en) | 2017-02-22 | 2018-08-30 | Twist Bioscience Corporation | Nucleic acid based data storage |
| WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| CA3066744A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| KR20200041897A (ko) * | 2017-08-01 | 2020-04-22 | 에이비 스튜디오 인코포레이티드 | 이중특이 항체 및 그의 용도 |
| GB2581620A (en) | 2017-09-11 | 2020-08-26 | Twist Bioscience Corp | GPCR binding proteins and synthesis thereof |
| CA3079613A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
| US20210238280A1 (en) | 2018-03-14 | 2021-08-05 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| WO2019222706A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| JP2021527103A (ja) * | 2018-06-14 | 2021-10-11 | バイオアトラ インコーポレイテッド | 多重特異性抗体構造体 |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN112566929A (zh) * | 2018-08-21 | 2021-03-26 | 生物蛋白有限公司 | 具pH选择性的条件活性蛋白质 |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| CA3130754A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| EP3927431A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AU2020224154A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3130628A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| JP2022522668A (ja) | 2019-02-26 | 2022-04-20 | ツイスト バイオサイエンス コーポレーション | 抗体を最適化するための変異体核酸ライブラリ |
| KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
| WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| WO2020257612A1 (en) | 2019-06-21 | 2020-12-24 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| WO2021084104A1 (en) | 2019-10-30 | 2021-05-06 | Bioinvent International Ab | Tetravalent antibody molecules |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| JP2023523011A (ja) | 2020-04-24 | 2023-06-01 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| CA3190755A1 (en) | 2020-08-26 | 2022-03-03 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
| KR20230074487A (ko) | 2020-08-26 | 2023-05-30 | 마렝고 테라퓨틱스, 인크. | Trbc1 또는 trbc2를 검출하는 방법 |
| CA3190766A1 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| EP4225786A2 (en) * | 2020-10-07 | 2023-08-16 | Amgen Inc. | Rational selection of building blocks for the assembly of multispecific antibodies |
| WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
| WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
| CA3232386A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
| WO2023044343A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
| WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
| WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| DK0575545T3 (da) | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylering af polypeptider |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU690088B2 (en) | 1992-11-24 | 1998-04-23 | G.D. Searle & Co. | Interleukin-3 (IL-3) multiple mutation polypeptides |
| GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| EP0720624B1 (en) | 1993-09-22 | 1998-11-25 | Medical Research Council | Retargeting antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| EP0954340B1 (en) | 1996-05-03 | 2007-06-27 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer |
| US7011812B1 (en) | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| EP1064027B1 (en) | 1998-03-27 | 2008-06-18 | Genentech, Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
| US7833528B2 (en) | 1998-06-22 | 2010-11-16 | Immunomedics, Inc. | Use of multispecific, non-covalent complexes for targeted delivery of therapeutics |
| DE60129741T2 (de) | 2000-06-20 | 2008-04-30 | Immunomedics, Inc. | Zielgerichtete kombinationsimmuntherapie für krebs und infektionskrankheiten |
| US6902734B2 (en) * | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| KR20030055274A (ko) | 2000-10-20 | 2003-07-02 | 츄가이 세이야꾸 가부시키가이샤 | 저분자화 트롬보포에틴 아고니스트 항체 |
| WO2002064746A2 (en) | 2001-02-14 | 2002-08-22 | Uab Research Foundation | Combined transductional and transcriptional targeting system for improved gene delivery |
| KR20040074587A (ko) | 2001-02-19 | 2004-08-25 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 인공 단백질 |
| US20050142539A1 (en) * | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
| WO2003091424A1 (fr) | 2002-04-26 | 2003-11-06 | Chugai Seiyaku Kabushiki Kaisha | Procede de criblage d'un anticorps agoniste |
| ES2442615T5 (es) * | 2002-07-18 | 2023-03-16 | Merus Nv | Producción recombinante de mezclas de anticuerpos |
| AU2013200009B2 (en) | 2002-07-18 | 2015-05-07 | Merus N.V. | Recombinant production of mixtures of antibodies |
| EP1605058B1 (en) * | 2003-01-21 | 2009-05-13 | Chugai Seiyaku Kabushiki Kaisha | Method of screening light chain of antibody light chains |
| JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
| US20090191213A9 (en) | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| WO2005030793A2 (en) * | 2003-09-24 | 2005-04-07 | Millennium Pharmaceuticals, Inc. | Antibodies which bind human cxcr3 |
| GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| EP1819731A4 (en) | 2004-12-08 | 2013-02-13 | Immunomedics Inc | METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| SI1699826T1 (sl) | 2005-01-05 | 2009-08-31 | Ngsges M B H F Star Biotechnol | Sintetske imunoglobulinske domene z vezavnimi lastnostmi, konstruiranimi v regijah molekule, različnih od regij, ki določajo komplementarnost |
| DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
| US9119828B2 (en) | 2005-09-23 | 2015-09-01 | The United States Of America As Represented By The Secretary Of The Army | Antibodies with simultaneous subsite specificities to protein and lipid epitopes |
| US20090220504A1 (en) | 2006-03-21 | 2009-09-03 | Anan Chuntharapai | Combinatorial therapy |
| DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
| GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| ES2566737T3 (es) | 2007-06-25 | 2016-04-15 | Esbatech, An Alcon Biomedical Research Unit Llc | Métodos de modificación de anticuerpos y anticuerpos modificados con propiedades funcionales mejoradas |
| US20090155275A1 (en) | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| JP2010538012A (ja) | 2007-08-28 | 2010-12-09 | バイオジェン アイデック マサチューセッツ インコーポレイテッド | Ｉｇｆ−１ｒの複数のエピトープに結合する組成物 |
| CL2008002856A1 (es) | 2007-09-26 | 2009-01-16 | Genentech Inc | Anticuerpo novedoso (anticuerpo anti-integrina a5b1; mol}ecula de ácido nucleico que lo codifica; vector y célula huesped; método de producción; composición farmacéutica que lo comprende; su uso para inhibir la angiogénesis y/o permeabilidad vascular y cáncer entre otras patologías; y método de detección de la integrina a5b1). |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| PT2307457T (pt) | 2008-06-25 | 2018-10-16 | Esbatech Alcon Biomed Res Unit | Anticorpos estáveis e solúveis que inibem o tnf |
| KR20110043643A (ko) | 2008-07-02 | 2011-04-27 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 인터루킨 6 면역치료제 |
| NZ590668A (en) | 2008-07-02 | 2012-12-21 | Emergent Product Dev Seattle | TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINS |
| JP2011526794A (ja) | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＧＦ−βアンタゴニスト多重標的結合性分子 |
| CA2729899A1 (en) * | 2008-07-14 | 2010-01-21 | Fred J. Stevens | Methods for systematic control of protein stability |
| WO2010014629A1 (en) | 2008-07-28 | 2010-02-04 | Trubion Pharmaceuticals, Inc. | Multi-specific binding proteins targeting b cell disorders |
| CA3038442A1 (en) | 2008-10-02 | 2010-04-08 | Aptevo Research And Development Llc | Cd86 antagonist multi-target binding proteins |
| CA2755640C (en) | 2009-03-20 | 2018-05-22 | Genentech, Inc. | Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr |
| BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
| DK2483310T3 (da) | 2009-09-29 | 2014-09-01 | Roche Glycart Ag | Bispecifik dødsreceptor-agonistiske antistoffer |
| US20120302492A1 (en) | 2009-10-30 | 2012-11-29 | Bayer Healthcare Llc | Antibody Mimetic Scaffolds |
| EP3778917A3 (en) | 2009-12-04 | 2021-06-09 | F. Hoffmann-La Roche AG | Multispecific antibodies, antibody analogs, compositions, and methods |
| PL2519543T3 (pl) | 2009-12-29 | 2016-12-30 | Białka wiążące heterodimery i ich zastosowania | |
| KR102432611B1 (ko) * | 2010-02-08 | 2022-08-16 | 리제너론 파마슈티칼스 인코포레이티드 | 일반적인 경쇄 마우스 |
| WO2011109726A2 (en) * | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
| RU2624027C2 (ru) * | 2010-04-23 | 2017-06-30 | Дженентек, Инк. | Получение гетеромультимерных белков |
| ES2741175T3 (es) | 2010-07-16 | 2020-02-10 | Bioatla Llc | Nuevos métodos de evolución de proteínas |
| CN103261220B (zh) * | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| MY166429A (en) | 2010-11-17 | 2018-06-26 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| MA34907B1 (fr) | 2011-01-14 | 2014-02-01 | Ucb Pharma Sa | Molécules d'anticorps se liant à il-17a et il-17f |
| EP2500073A1 (en) | 2011-03-17 | 2012-09-19 | ChromaCon AG | Method for identification and purification of multi-specific polypeptides |
| CN107936121B (zh) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
| US20150045540A1 (en) | 2011-06-28 | 2015-02-12 | Sea Lane Biotechnologies, Llc | Multispecific stacked variable domain binding proteins |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| EP2543680A1 (en) | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| WO2013049254A1 (en) | 2011-09-26 | 2013-04-04 | Jn Biosciences Llc | Hybrid constant regions |
| CN114133454A (zh) | 2012-03-14 | 2022-03-04 | 瑞泽恩制药公司 | 多特异性抗原结合分子及其用途 |
| US20150086584A1 (en) | 2012-03-22 | 2015-03-26 | University Of Miami | Multi-specific binding agents |
| EP3553089A1 (en) | 2012-05-10 | 2019-10-16 | Bioatla, LLC | Multi-specific monoclonal antibodies |
| WO2013174873A1 (en) | 2012-05-24 | 2013-11-28 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| EP2880057A4 (en) | 2012-08-02 | 2016-03-23 | Jn Biosciences Llc | MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL |
| KR20140036905A (ko) | 2012-09-18 | 2014-03-26 | 삼성전자주식회사 | 이중특이 항체를 포함하는 단백질 복합체 |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
-
2013
- 2013-05-10 EP EP19174963.9A patent/EP3553089A1/en active Pending
- 2013-05-10 IN IN9417DEN2014 patent/IN2014DN09417A/en unknown
- 2013-05-10 CA CA2872908A patent/CA2872908C/en active Active
- 2013-05-10 CN CN201810258801.6A patent/CN108690132B/zh active Active
- 2013-05-10 JP JP2015511761A patent/JP6267689B2/ja active Active
- 2013-05-10 AU AU2013259276A patent/AU2013259276B2/en active Active
- 2013-05-10 EP EP13788439.1A patent/EP2847231B1/en active Active
- 2013-05-10 KR KR1020197004783A patent/KR102023401B1/ko active IP Right Grant
- 2013-05-10 US US14/399,617 patent/US9969813B2/en active Active
- 2013-05-10 WO PCT/US2013/040575 patent/WO2013170168A1/en active Application Filing
- 2013-05-10 DK DK13788439.1T patent/DK2847231T3/da active
- 2013-05-10 KR KR1020147033427A patent/KR101951641B1/ko active IP Right Grant
- 2013-05-10 CA CA3202536A patent/CA3202536A1/en active Pending
- 2013-05-10 KR KR1020197017228A patent/KR102089526B1/ko active IP Right Grant
- 2013-05-10 MX MX2019001355A patent/MX2019001355A/es unknown
- 2013-05-10 CA CA3051210A patent/CA3051210A1/en active Pending
- 2013-05-10 CN CN201380035170.7A patent/CN104583239B/zh active Active
- 2013-05-10 ES ES13788439T patent/ES2749200T3/es active Active
- 2013-05-10 MX MX2014013590A patent/MX362705B/es active IP Right Grant
-
2015
- 2015-08-26 HK HK15108289.6A patent/HK1210620A1/xx unknown
-
2017
- 2017-12-22 JP JP2017246602A patent/JP6465953B2/ja active Active
-
2018
- 2018-02-16 AU AU2018201159A patent/AU2018201159B2/en active Active
- 2018-03-23 US US15/934,596 patent/US20180237543A1/en not_active Abandoned
-
2019
- 2019-01-07 JP JP2019000631A patent/JP6723392B2/ja active Active
- 2019-01-31 US US16/264,028 patent/US10696750B2/en active Active
-
2020
- 2020-03-25 AU AU2020202133A patent/AU2020202133B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09417A (US07915450-20110329-C00039.png) | ||
| PH12017500915A1 (en) | Cd47 antibodies, methods, and uses | |
| PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
| MX360368B (es) | Regiones de anticuerpo modificado y sus usos. | |
| PH12015502565A1 (en) | Anti-transferrin receptor antibodies and methods of use | |
| PH12014501758A1 (en) | Cd47 antibodies and methods of use thereof | |
| WO2013064701A3 (en) | Specific antibodies and their isolation with anti-idiotypic antibodies | |
| MX364329B (es) | Conjugados del anticuerpo pirrolobenzodiazepina. | |
| EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
| NZ739622A (en) | Antibodies to tau | |
| EA201492101A1 (ru) | Антитела против fcrn | |
| TN2013000292A1 (en) | Antibody molecules which bind il-17a and il-17f | |
| EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
| SG10201703798YA (en) | Antibodies with modified affinity to fcrn that promote antigen clearance | |
| MX2014000363A (es) | Anticuerpos monoclonales inhibidores anti-factor xii-xiia. | |
| WO2013021279A3 (en) | Highly galactosylated antibodies | |
| PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
| WO2011109726A3 (en) | Homologous multi-specific antibodies | |
| IN2015DN00634A (US07915450-20110329-C00039.png) | ||
| MX350335B (es) | Anticuerpos que enlazan alfa-v beta-8 integrina. | |
| WO2013186630A3 (en) | Humanized antibodies to ca215 | |
| NZ743971A (en) | Antibodies to tau |
